drugset / Trial / NCT03602690
Evaluation of Third-line cART Regimen in Cambodia (3DICAM)
NaSingle-groupOpen-labelTreatment
Summary
The study aims to evaluate the virological effectiveness of a third-line regimen combining dolutegravir (DTG), ritonavir-boosted darunavir (DRV/r) and optimized NRTI in Cambodian HIV-infected adults, who failed a protease inhibitors (PI)-based second-line regimen despite 3 months of boosted adherence counseling (BAC).
Timeline
- Start
- 2018-10-04
- Primary completion
- 2022-04-11
- Completion
- 2022-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | — | — |
| Subject | Darunavir | Small molecule | 600 mg | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Tenofovir | Small molecule | — | — |
| Subject | Zidovudine | Small molecule | — | — |
| Background | Dolutegravir | Other / unclassified | 50 mg | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |